Baird Reiterates a 'Neutral' Rating on Genzyme (GENZ); Long-Term Implications Still Evolving
Tweet Send to a Friend
Baird reiterates a 'Neutral' rating on Genzyme (Nasdaq: GENZ), price target $54.
Baird analyst says, "While we are encouraged Cerezyme ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "While we are encouraged Cerezyme ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
